Titans of Science: Andrew Pollard on vaccines, Oxford-AstraZeneca and the future of vaccination

Overview

In the Naked Scientists Titans of Science episode, Rhys James interviews Sir Andrew Pollard, exploring how vaccines educate the immune system and why booster schedules matter. Pollard reflects on decades of public health progress and the not-for-profit model that helped expand access during the COVID-19 pandemic. The discussion covers the Oxford-AstraZeneca vaccine, policy decisions by the JCVI, and the potential of mRNA vaccines for the future.

• Understanding how vaccines train immunity
• The Oxford-AstraZeneca vaccine and vaccines at scale
• Policy decisions and cost effectiveness in public health
• The promise of RNA vaccines for future outbreaks

Overview

In this episode of the Naked Scientists Titans of Science, Rhys James speaks with Sir Andrew Pollard, a leading figure in vaccine research who helped drive the Oxford vaccine program during the COVID-19 pandemic. The conversation covers the science of vaccines, their historical impact, and the pathways that accelerate vaccine development within public health systems.

Vaccine science foundations

Pollard explains that vaccines work by training the immune system to recognise foreign elements on pathogens in a safe way. This education means that when real pathogens are encountered, the immune system responds rapidly and effectively. He notes that vaccine effectiveness varies with the pathogen and its ability to mutate; some, like measles, remain relatively stable and confer long-lasting protection, while others such as influenza and coronavirus require updates and boosters to maintain protection against infection or severe disease.

Global impact of vaccines

The hosts discuss the staggering global health benefits of vaccination. Pollard cites estimates of 3 to 5 million lives saved each year through global vaccine programs, the eradication of smallpox, and a roughly 90 percent reduction in measles mortality worldwide. He reflects on how pediatric practice has changed as a result of vaccines, with many previously common diseases now rarely seen by today’s trainees in Oxford.

Vaccine types and design decisions

The discussion traverses different vaccine strategies, including live attenuated, killed, and toxoid-based vaccines. Tetanus toxoid is given as an example of how toxins can be neutralised by vaccination. The shingles vaccine demonstrates targeting surface proteins to boost immunity. The conversation also touches historic vaccine approaches that weaken pathogens and the role of historical knowledge in choosing vaccine types, alongside safety and manufacturing considerations.

The Oxford AstraZeneca collaboration and manufacturing at scale

Pollard describes how Oxford provides vaccine design and clinical development expertise while manufacturing scale requires a partner with global production capabilities. AstraZeneca contributed manufacturing capacity and distribution reach across dozens of sites, enabling rapid, large-scale deployment. A key aim was not-for-profit distribution to ensure equitable access, including in lower income regions, focusing on protecting the most vulnerable populations.

Backbone technology and cross-context use

The backbone viral vector used in the Oxford vaccine is discussed as a Trojan horse approach, delivering a gene fragment to trigger an immune response. This technology formed the backbone for other vaccines, including Ebola, illustrating how platform technologies can be redeployed across diseases to accelerate development.

Safety: rare adverse events

The podcast addresses very rare events associated with adenoviral vector vaccines, such as brain blood clots with low platelets. Observed frequencies vary by country, and while the exact mechanism remains uncertain, researchers emphasize the difficulty of testing this in animal models. Pollard acknowledges the ongoing need to understand and mitigate such risks while weighing them against the benefits of preventing death and severe disease.

RNA vaccines and the future

The potential of RNA vaccine technology is highlighted for its rapid manufacturing and ease of iteration. Pollard notes that RNA platforms could enable rapid scale-up for future outbreaks and allow testing of multiple designs quickly. He discusses research applications beyond COVID-19, including plague vaccines, underscoring a broader potential for RNA-based approaches in medicine.

Decision making in public health

The Joint Committee on Vaccination and Immunisation (JCVI) role is outlined: assessing disease burden, vaccine availability, safety, and impact, and applying treasury-defined cost-effectiveness thresholds to choices about schedule changes and new vaccines. Pollard explains how decisions during the pandemic were made with incomplete data, balancing urgency and ongoing data collection, and how the system continually revises guidance as new information emerges.

Legacy and outlook

The episode closes with reflections on the enduring importance of vaccines in public health, the evolution of vaccine technology, and the promise of safer, faster RNA-based vaccines that could transform medicine beyond infectious diseases.